Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/6452
Title: | Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study | Authors: | Belpomme, D. Krakowski, I. Beaudin, M. Petit, T. Canon, J.L. JANSSENS, Jaak Gauthier, S. de Pauw, A. Moreau, V. Kayitalire, I. |
Issue Date: | 2003 | Publisher: | ACADEMIC PRESS INC ELSEVIER SCIENCE | Source: | Gynecologic oncology, 91(1). p. 32-38 | Abstract: | Objective. This phase II study was performed to evaluate the activity and toxicity of gemcitabine plus cisplatin as first-line treatment of advanced epithelial ovarian cancer. Methods. Chemonaive patients with histologically or cytologically confirmed FIGO stage III or IV epithelial ovarian carcinoma were enrolled. Patients received cisplatin 75 mg/m(2) on Day 1 and gemcitabine 1250 mg/m(2) on Days 1 (after cisplatin) and 8 of a 21-day cycle. Results. Of the 42 female patients (median age 60 years) enrolled, 81% had a Zubrod performance status of 0 or 1. Among the 37 response-evaluable patients, there were 5 (13.5%) pathological complete responses (CRs), 16 (43.2%) pathological partial responses (PRs), and 3 (8.1%) clinical PRs, for an overall response rate of 64.9% (95% CI: 47.4-79.8%) and a pathological response rate of 56.8%. Per an intent-to-treat analysis, the overall response rate was 57.1% (95% CI: 41.0-72.3%). After a median follow-up time of 15.8 months, the median survival was 24.0 months and median progression-free survival was 13.4 months. Grade 3/4 neutropenia and thrombocytopenia occurred in 69.0 and 33.3% of patients, respectively, with no febrile neutropenia or hemorrhage. Grade 3/4 nausea and vomiting occurred in 35.7% and grade 3 alopecia in 21.4% of the patients. One patient died due to a toxicity-related death (dyspnea). Conclusions. Gemcitabine plus cisplatin is active and feasible as first-line treatment of advanced epithelial ovarian cancer. Further clinical trials adding gemcitabine to first-line treatment seem warranted. (C) 2003 Elsevier Inc. All rights reserved. | Keywords: | gemcitabine; cisplatin; ovarian cancer; chemonaive | Document URI: | http://hdl.handle.net/1942/6452 | ISSN: | 0090-8258 | e-ISSN: | 1095-6859 | DOI: | 10.1016/S0090-8258(03)00413-X | ISI #: | 000185731200005 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
20
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
13
checked on Oct 10, 2024
Page view(s)
68
checked on Jun 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.